National Cancer Institute Notice of Meeting, 52960-52961 [2011-21679]
Download as PDF
<![CDATA[
52960
Federal Register / Vol. 76, No. 164 / Wednesday, August 24, 2011 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Ronald Adkins, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2206,
MSC 7890, Bethesda, MD 20892, 301–495–
4511, ronald.adkins@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: ACL and Bone.
Date: September 29–30, 2011.
Time: 10 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Baljit S Moonga, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4214,
MSC 7806, Bethesda, MD 20892, 301–435–
1777, moongabs@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 18, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21683 Filed 8–23–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
wreier-aviles on DSKGBLS3C1PROD with NOTICES
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Discovery,
Imaging, and Therapeutics.
Date: October 5–6, 2011.
Time: 8 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marriott Bethesda, 5151 Pooks Hill
Road, Bethesda, MD 20814.
VerDate Mar<15>2010
15:40 Aug 23, 2011
Jkt 223001
Contact Person: Peter J. Wirth, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 8131, Bethesda,
MD 20892–8328, 301–496–7565,
pw2q@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, K08 Grant
Application.
Date: October 12, 2011.
Time: 5 to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Crystal City, 2799
Jefferson Davis Highway, Arlington, VA
22202.
Contact Person: Lynn M Amende, PhD,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Boulevard, Room
8105, Bethesda, MD 20892–8328, 301–451–
4759, amendel@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Mechanisms of Cell Signaling in Cancer.
Date: October 13–14, 2011.
Time: 3 to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Majed M. Hamawy, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 8135,
Bethesda, MD 20852, 301–594–5659,
mh101v@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Strategic
Partnering to Evaluate Cancer Signature
(SPECS II).
Date: October 18–19, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Lorien Hotel and Spa, 1600 King
Street, Alexandria, VA 22314.
Contact Person: Marvin L. Salin, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 7073,
Bethesda, MD 20892–8329, 301–496–0694,
msalin@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: August 18, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21682 Filed 8–23–11; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Cancer Institute Clinical Trials
and Translational Research Advisory
Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Cancer
Institute Clinical Trials and Translational
Research Advisory Committee.
Date: November 9, 2011.
Time: 9 a.m. to 4 p.m.
Agenda: Strategic Discussion of NCI’s
Clinical and Translational Research
Programs.
Place: National Institutes of Health,
Building 31, C-wing, 6th Floor, 31 Center
Drive, Conference Room 10, Bethesda, MD
20892.
Contact Person: Sheila A. Prindiville, MD,
MPH, Director, Coordinating Center for
Clinical Trials, Office of the Director,
National Cancer Institute, National Institutes
of Health, 6120 Executive Blvd., 3rd Floor
Suite, Bethesda, MD 20892, 301–451–5048,
prindivs@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
E:\FR\FM\24AUN1.SGM
24AUN1
Federal Register / Vol. 76, No. 164 / Wednesday, August 24, 2011 / Notices
Dated: August 18, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2011–21679 Filed 8–23–11; 8:45 am]
Prospective Grant of Exclusive
License: Devices for Clearing Mucus
From Endotracheal Tubes
National Institutes of Health
BILLING CODE 4140–01–P
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
wreier-aviles on DSKGBLS3C1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Neuro Therapeutics Course.
Date: August 31, 2011.
Time: 2:45 p.m. to 5 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Phillip F. Wiethorn,
Scientific Review Officer, DHHS/NIH/
NINDS/DER/SRB, 6001 Executive Boulevard,
MSC 9529, Neuroscience Center, Room 3203,
Bethesda, MD 20892–9529, 301–496–5388,
wiethorp@ninds.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: August 18, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–21678 Filed 8–23–11; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
15:40 Aug 23, 2011
Jkt 223001
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of a worldwide
exclusive license, to practice the
invention embodied in: HHS Ref. No. E–
061–2004/0 ‘‘Mucus Shaving Apparatus
for Endotracheal Tubes’’; U.S. Patent
7,051,737 to EndOclear, LLC, a
company incorporated under the laws of
the State of Michigan having its
headquarters in Petoskey, Michigan.
The United States of America is the
assignee of the rights of the above
inventions. The contemplated exclusive
license may be granted in a field of use
limited to devices for clearing mucus
from endotracheal tubes.
DATES: Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before September 23, 2011 will be
considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Michael A. Shmilovich, Esq., Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
5019; Facsimile: (301) 402–0220; E-mail:
shmilovm@mail.nih.gov. A signed
confidentiality nondisclosure agreement
will be required to receive copies of any
patent applications that have not been
published or issued by the United States
Patent and Trademark Office or the
World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: The patent
intended for licensure covers an
endotracheal tube cleaning apparatus
which is inserted into the inside of an
endotracheal tube to shave away mucus
deposits. Mucus deposits contribute to
bacterial growth and put intubated
patients at risk for ventilator associated
pneumonia (VAP). The preferred
embodiment as recited in the claims is
a cleaning apparatus with a flexible
central tube and an inflatable balloon at
its distal end. Affixed to the inflatable
SUMMARY:
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
52961
balloon are one or more shaving rings
each having a squared leading edge to
shave away mucus accumulations. In
operation, the uninflated cleaning
apparatus is inserted into the
endotracheal tube and the balloon is
then inflated by a suitable inflation
device, such as a syringe, until the
balloon’s shaving rings are pressed
against the inside surface of the
endotracheal tube. The cleaning
apparatus is then pulled out of the
endotracheal tube to shave off mucus
deposits.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
within thirty (30) days from the date of
this published notice, NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: August 16, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–21685 Filed 8–23–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
Agency Information Collection
Activities: Form N–300; Revision of an
Existing Information Collection;
Comment Request
60-Day Notice of Information
Collection Under Review; Form N–300,
Application to File Declaration of
Intention; OMB Control No. 1615–0078.
ACTION:
The Department Homeland Security,
U.S. Citizenship and Immigration
Services (USCIS) will be submitting the
following information collection request
for review and clearance in accordance
with the Paperwork Reduction Act of
1995. The information collection is
published to obtain comments from the
E:\FR\FM\24AUN1.SGM
24AUN1
]]>Agencies
[Federal Register Volume 76, Number 164 (Wednesday, August 24, 2011)]
[Notices]
[Pages 52960-52961]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-21679]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute Notice of Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Cancer Institute Clinical Trials and Translational Research
Advisory Committee.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: National Cancer Institute Clinical Trials and
Translational Research Advisory Committee.
Date: November 9, 2011.
Time: 9 a.m. to 4 p.m.
Agenda: Strategic Discussion of NCI's Clinical and Translational
Research Programs.
Place: National Institutes of Health, Building 31, C-wing, 6th
Floor, 31 Center Drive, Conference Room 10, Bethesda, MD 20892.
Contact Person: Sheila A. Prindiville, MD, MPH, Director,
Coordinating Center for Clinical Trials, Office of the Director,
National Cancer Institute, National Institutes of Health, 6120
Executive Blvd., 3rd Floor Suite, Bethesda, MD 20892, 301-451-5048,
prindivs@mail.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
[[Page 52961]]
Dated: August 18, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-21679 Filed 8-23-11; 8:45 am]
BILLING CODE 4140-01-P
